Comprehensive Genomic Profiling for Precision Oncology
The GENONCO™ Cancer RT-PCR & NGS Test is a cutting-edge molecular diagnostic solution designed to detect clinically relevant genetic mutations, gene fusions, and expression markers associated with various cancers. Developed for precision oncology, the test utilizes both real-time RT-PCR and next-generation sequencing (NGS) platforms, enabling accurate, high-throughput identification of somatic and germline alterations.
GENONCO™ supports personalized cancer treatment by offering insights into targetable mutations and resistance mechanisms across solid tumors and hematologic malignancies. With panels covering key oncogenes and tumor suppressor genes, this test is ideal for clinical decision-making, treatment selection, and monitoring therapeutic response.
Dual-platform support: RT-PCR + NGS-based mutation profiling
Detects SNVs, Indels, CNVs, fusions, and gene expression changes
Panels available for lung, breast, colon, ovarian, prostate, and hematologic cancers
High sensitivity: detects low-frequency variants
Compatible with FFPE, blood, plasma, and cfDNA samples
Built-in quality controls and ISO13485-compliant manufacturing
Comprehensive genomic profiling (CGP)
Targeted therapy selection
Minimal residual disease (MRD) monitoring
Companion diagnostics support
Prognostic and diagnostic stratification
| Parameter | RT-PCR | NGS |
|---|---|---|
| Assay Type | qRT-PCR | Amplicon-based or hybrid capture |
| Turnaround Time | 3–4 hours | 24–48 hours |
| Sample Types | FFPE, blood, plasma, tissue | FFPE, cfDNA, RNA, fresh/frozen tissue |
| Targets | Mutation-specific panels | Panels with 50–500+ genes |
| Sensitivity | ≥95% | Variant allele frequency ≥1% |
| Platform Compatibility | All major qPCR instruments | Illumina®, Ion Torrent™ compatible |
| Bioinformatics | Not required | Provided with full report |
Copyright © 2025 https://probgenbiotech.com/ All Rights Reserved.